

FIG. 1A




FIG. 1B

FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 4A




FIG. 4B




FIG. 5A




FIG. 5B




FIG. 6A





FIG. 6B



7/13





FIG. 7

FIG. 8A




MTRV001

FIG. 8B



PLY-DM

FIG. 8C



PBS




FIG. 9




FIG. 10






FIG. 10
CONTINUED



SRM: Safety Review Meeting.

All 3 participants in Cohort 1 will receive MTRV001 in an open-label manner. In Cohorts 2 through 5, the first 2 participants in each cohort will receive MTRV001 in an open-label manner prior to administration of the double-blind study intervention (MTRV001 or placebo) in the remainder of the cohorts.

FIG. 10
CONTINUED



AE: adverse event; IM: intramuscular(ly).

Potential participants will be screened within 28 days prior to Visit 2 (Day 1).

Study intervention will be administered by IM injection in the deltoid muscle of the non-dominant arm (or dominant arm if participant prefers) at Visits 2 (Day 1) and 4 (Day 29 [± 2 days]) at the study site. Participants will be observed by study personnel at the study site for 30 minutes following each administration of study intervention, and any adverse events will be recorded.

Using a diary card, each participant will record oral temperature (evaluated using provided thermometers) and local and systemic AEs daily for 7 days after each administration of study intervention.

In addition, each participant will be contacted by telephone at approximately 24 hours, 72 hours, 7 days, and 13 days following each administration of study intervention for safety assessments and review of the diary. Between Visits 6 (Day 57 [± 4 days]) and 7 (Day 210 [± 14 days]), each participant will be contacted by telephone at monthly intervals (Days 90, 120, 150, 180 [± 3 days]) for safety follow-up.

FIG. 11